AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and…
An institutional-grade, numbers-driven thesis on ABBV — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates AbbVie Inc. (ABBV) 61/100 with a 12-month base-case forecast of $283.92 — +16.4% versus the current price of $243.87. AbbVie Inc. trades at $243.87 in the Healthcare sector, with a market capitalisation of $430.87B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for ABBV is $283.92, implying +16.4% versus the current price. The model's 12-month scenario range runs from $264.00 (bear) to $309.23 (bull), with a base case of $278.45.
On the fundamentals, AbbVie shows a P/E of 68.7, trailing revenue of $61.16B, revenue growth of +8.6% YoY, a dividend yield of 2.80%. This page also tracks ABBV's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ABBV currently carries a TradersQuant composite score of 61/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $283.92 implies +16.4% from $243.87. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for ABBV is $283.92, about +16.4% versus the latest price of $243.87. Consensus is based on 41 analysts.
TradersQuant's 12-month model forecast for ABBV is a base case of $278.45, ranging from $264.00 (bear) to $309.23 (bull), an expected return of +14.2%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ABBV over the next 12 months is $278.45 in the base case (bear $264.00, bull $309.23), versus today's price of $243.87. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ABBV — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ABBV's fair value at $283.92, implying +16.4% of expected upside versus the current price.
Yes — AbbVie pays a dividend yielding 2.80% (about $6.83 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
